Cancer Harboring BRAF Alterations clinical trials at UCSF
1 research study open to eligible people
Cancer harboring BRAF alterations means cancer cells have a change in the BRAF gene. UCSF is testing a medicine called plixorafenib to check safety and response in patients. UCSF is collecting lab results and scans to record treatment effects and side effects.
FORE8394 in Participants With Cancer Harboring BRAF Alterations
open to eligible people ages 10 years and up
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare BRAF V600-mutated solid tumors, melanoma, thyroid, or recurrent primary CNS tumors.
San Francisco, California and other locations
Last updated: